On this episode of The Harvest Podcast, Carmel Fisher sits down with Giorgio R. Saumat, Chairman and CEO of Earth Science Tech, Inc. (OTC: ETST), to discuss the company’s disciplined operating model and long‑term growth strategy. Saumat outlines ETST’s vertically integrated healthcare platform—spanning telehealth, compounding pharmaceuticals, and patient fulfillment—while emphasizing the company’s strong balance sheet, positive cash flow, and multi‑year track record of avoiding dilutive capital raises.

The conversation also explores ETST’s diversification initiatives, profitability trajectory, and readiness for scaled expansion as the company positions itself for a potential uplist. For investors and stakeholders seeking clarity on ETST’s operational focus and capital‑markets strategy, this discussion offers a clear, grounded view of where the company is headed.

Learn More: www.harvestcomms.com

Disclaimer:

The Harvest podcast is for informational and educational purposes only. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company or institution mentioned. The content of this podcast does not constitute investment, legal, or tax advice.

Investing in securities involves risk, including the potential loss of principal. Please be aware that the stock market can be volatile and investment values can fluctuate. By listening to this podcast, you agree to not hold the host, guests, producers, or any affiliated companies liable for any investment decisions you make.

Always do your own due diligence and invest responsibly.

The Panguna Mine in Bougainville contains an estimated $100 billion in proven copper and gold reserves; nearly 1% of global gold reserves and copper resources equal to 70% of Canada's total. Shuttered since 1989 due to civil war, it remains one of the world's largest undeveloped ore bodies. In this extraordinary conversation, Numa Numa Resources Chairman & CEO John D. Kuhns explains how his company secured what no other mining firm has achieved: binding agreements with the Panguna landowners and Bougainville's government to develop the mine.

John D. Kuhns, Chairman & CEO of Numa Numa Resources, discusses his company's unprecedented agreements to develop Bougainville's Panguna Mine (a $100 billion copper-gold resource that's been shuttered since 1989).

Kuhns explains how decade-long relationships with landowner clans create competitive advantages traditional miners can't replicate, addresses sovereignty risk as Bougainville pursues independence from Papua New Guinea, and reveals why China's strategic interest in the region makes Western investment urgent. Topics include capital requirements for mine restart, profit-sharing structures, Numa Numa's planned public listing, and why this tier-one asset is positioned to help fill the looming global copper supply gap. A geopolitically charged conversation about resources, independence, and frontier market opportunity.

Perfect for: Resource investors, geopolitical analysts, family offices evaluating frontier market opportunities, institutional investors interested in copper-gold exposure, and anyone tracking U.S.-China strategic competition in the Pacific.

Critical Context: Goldman Sachs projects gold at $4,900/oz by December 2026. Global copper demand is set to double by 2035 with supply pipelines critically constrained. The Panguna Mine's 547.15 metric tons of gold and 5.3 million metric tons of copper are proven reserves—not exploration targets. This isn't a speculative junior miner; it's a fully explored, previously producing tier-one asset in a geopolitically strategic location.

Disclaimer:

The Harvest podcast is for informational and educational purposes only. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company or institution mentioned. The content of this podcast does not constitute investment, legal, or tax advice.

Investing in securities involves risk, including the potential loss of principal. Please be aware that the stock market can be volatile and investment values can fluctuate. By listening to this podcast, you agree to not hold the host, guests, producers, or any affiliated companies liable for any investment decisions you make.

Always do your own due diligence and invest responsibly.

Join us for an exclusive conversation with John Lai, CEO of PetVivo Holdings, Inc. (NASDAQ: PETV), as we explore how this biomedical device company is positioning itself at the intersection of veterinary therapeutics and the explosive AI-driven preventive pet care revolution.

What You'll Discover:

• How Spryng, PetVivo's intra-articular injection for managing lameness and osteoarthritis in dogs and horses, is penetrating the veterinary clinic market
• The strategic significance of the Digital Landia partnership and what AgenticPet's viral adoption (1,000+ beta users in under 72 hours) means for PetVivo's distribution strategy
• Why the shift from reactive to preventive pet care creates a massive tailwind for PetVivo's commercial expansion across 8,500+ potential veterinary clinic partners
• EXCLUSIVE: Lai's roadmap for scaling beyond the company's lead product into both veterinary and human clinical applications
• How PetVivo plans to capture value from the convergence of AI diagnostics and therapeutic interventions in the $30+ billion pet healthcare market

Lai reveals the company's capital allocation strategy, pipeline priorities, and competitive advantages as veterinary medicine undergoes its biggest transformation in decades. With pet owners demonstrating unprecedented demand for proactive health solutions, discover why PetVivo believes it's positioned to deliver both better patient outcomes and sustainable shareholder returns.

Host: Carmel Fisher

Perfect for: Healthcare investors, veterinary industry professionals, biomedical device sector analysts, and anyone tracking the intersection of AI and animal health.

Key Topics: Veterinary therapeutics, biomedical devices, osteoarthritis treatment, AI-driven diagnostics, preventive care models, veterinary clinic distribution, pet healthcare market dynamics, strategic partnerships

This episode examines how established therapeutic companies can leverage emerging AI platforms to accelerate market penetration and create new revenue opportunities.

Meet the team in person:

DealFlow Discovery Conference,

Borgata Hotel, Casino and Spa (Atlantic City, NJ) - Jan. 28-29, 2026

Disclaimer:

The Harvest podcast is for informational and educational purposes only. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company or institution mentioned. The content of this podcast does not constitute investment, legal, or tax advice.

Investing in securities involves risk, including the potential loss of principal. Please be aware that the stock market can be volatile and investment values can fluctuate. By listening to this podcast, you agree to not hold the host, guests, producers, or any affiliated companies liable for any investment decisions you make.

Always do your own due diligence and invest responsibly.